Brookfield Asset Management and Warburg Pincus led global private equity and venture capital deal activity in July, driving total monthly deal value to $43.31 billion — the second consecutive monthly increase after eighteen months of subdued deployment. The volume marks a 28% sequential gain from June's $33.8 billion and the highest single-month tally since November 2023, when dealflow briefly touched $47 billion before retreating through Q1.
Brookfield closed its $6.8 billion acquisition of a European renewable energy portfolio from NextEra Energy Partners in mid-July, the largest infrastructure take-private of the year. Warburg Pincus followed with a $4.2 billion majority stake in Teladoc Health's chronic care division, carved out in a structured separation that left the parent company with $1.1 billion in net proceeds and a 19% retained interest. The two transactions alone accounted for 25% of the month's total deal value. Beyond the marquee names, mid-market activity also firmed: 63 transactions above $500 million closed in July, up from 49 in June and 41 in May.
The uptick matters because it arrives against a backdrop of persistent exit gridlock and cautious LP capital calls. Brookfield's renewable bet reflects conviction that infrastructure assets with contracted cashflows can clear the 12-14% net IRR hurdle even at current financing costs, a thesis that diverges sharply from software and tech-enabled services plays still trading at 8-10x EBITDA multiples with unrealized basis risk. Warburg's healthcare carve-out underscores a related theme: corporate divestitures now supply better entry multiples than competitive auctions, especially where sellers prioritize speed and certainty over last-dollar pricing. The chronic care unit traded at 9.2x forward EBITDA, a 15% discount to the 10.8x median for venture-backed digital health assets sold in bilateral processes over the past six months.
Second-order effects ripple through the LP base. Deployment velocity at this pace — if sustained through Q3 — would imply annualized deal volume near $520 billion, still below the $680 billion 2021 peak but materially above the $410 billion run rate that prevailed from Q4 2023 through Q1 2024. That acceleration tightens the gap between capital called and capital distributed, a ratio that has sat uncomfortably above 1.8x for the past eight quarters. Family offices and endowments watching their private allocation drift above policy weight now face a narrower window to rebalance before the next vintage-year capital call cycle begins in earnest.
Operators and allocators should watch for Brookfield's $28 billion Global Transition Fund II to begin marking first closes in September, a bellwether for institutional appetite at the infrastructure mega-fund tier. Warburg Pincus is expected to launch its $18 billion flagship Fund XIV in Q4, targeting a first close by January. If both vehicles clear their initial fundraising hurdles without extending timelines, it confirms that LPs are willing to meet deployment with fresh commitments rather than starve existing managers. Separately, corporate carve-out deal count is tracking 18% ahead of last year's pace; any deceleration in September would suggest the July spike was inventory clearing, not trend reversal.
Brookfield's renewable portfolio acquisition closed at a 6.2% unlevered yield on contracted cashflows, implying the firm modeled financing at 5.8% and accepted 40 basis points of spread compression since initial diligence began in March.